Efficacy and safety of imidafenacin in female overactive bladder patients with hypertension.

Efficacy and safety of imidafenacin in female overactive bladder patients with hypertension. - Efficacy and safety of imidafenacin in female overactive bladder patients with hypertension.(East Noah Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011998

Enrollment

Registered

2013-10-15

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

Administration of imidafenacin hypertension

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: overactive bladder patients and whose OABSS Q2 score is over 2 and Q3 is over 2

Exclusion criteria

Exclusion criteria: stress urinary incontinence patient, patient who have urinary dysfunction, allergy for anticholinergic agents

Design outcomes

Primary

Measure	Time frame
overactive bladder symptom score	—

Secondary

Measure	Time frame
frequency volume chart, Athens Insomnia Scale Actigram, Nocturia Quality-of-Life Questionnare, adverse effects, patient background, uroflowmetry, residual urine volume	—

Countries

Japan

Contacts

Public ContactYukiko Kouchi

Tokyo Women's Medical University Hospital Department of Urology

ykouchi@kc.twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026